Childhood obesity and its impact on the development of adolescent PCOS

Seminars in Reproductive Medicine

Volumn 32, Issue 3, 2014, Pages 202-213

  Anderson, Amy D ^a   Solorzano, Christine M Burt ^a   McCartney, Christopher R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

adolescent; hyperandrogenemia; obesity; overweight; polycystic ovary syndrome

Indexed keywords

ANDROGEN; CYTOKINE; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADOLESCENT DISEASE; ADRENAL GLAND; ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; ARTICLE; BARIATRIC SURGERY; BIOAVAILABILITY; CHILDHOOD OBESITY; COMORBIDITY; FAT MASS; FEMALE FERTILITY; HORMONE RELEASE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; METABOLIC SYNDROME X; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PUBERTY; SIGNAL TRANSDUCTION; STEROID METABOLISM; STEROIDOGENESIS; TESTOSTERONE BLOOD LEVEL; WEIGHT REDUCTION; ADOLESCENT; BODY MASS; COMPLICATION; FEMALE; POLYCYSTIC OVARY SYNDROME;

ADOLESCENT; BODY MASS INDEX; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; PEDIATRIC OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 84898456094     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0034-1371092     Document Type: Article

References (158)

1. [Anonymous] ACOG Committee on Practice Bulletins - Gynecology ACOG Practice Bulletin No. 108: polycystic ovary syndrome. Obstet Gynecol: 2009; 114 4 936 949
2. March W. A., Moore V. M., Willson K. J., Phillips D. I., Norman R. J., Davies M. J. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod: 2010; 25 2 544 551
3. Moran L. J., Misso M. L., Wild R. A., Norman R. J. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update: 2010; 16 4 347 363
4. Lim S. S., Davies M. J., Norman R. J., Moran L. J. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update: 2012; 18 6 618 637
5. McCartney C. R., Prendergast K. A., Chhabra S., et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab: 2006; 91 5 1714 1722
6. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond): 2008; 32 7 1035 1041 (Pubitemid 351986206)
7. Ogden C. L., Carroll M. D., Kit B. K., Flegal K. M. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA: 2012; 307 5 483 490
8. Alvarez-Blasco F., Botella-Carretero J. I., San Millán J. L., Escobar-Morreale H. F. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med: 2006; 166 19 2081 2086 (Pubitemid 44631395)
9. Yildiz B. O., Knochenhauer E. S., Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab: 2008; 93 1 162 168
10. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev: 2012; 33 6 981 1030
11. Ogden C. L., Carroll M. D., Kit B. K., Flegal K. M. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief: 2012; 82 1 8
12. Legro R. S. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med: 2012; 30 6 496 506
13. Ezeh U., Yildiz B. O., Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab: 2013; 98 6 E1088 E1096
14. Escobar-Morreale H. F., San Millán J. L. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab: 2007; 18 7 266 272 (Pubitemid 47332217)
15. Barber T. M., Golding S. J., Alvey C., et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2008; 93 3 999 1004 (Pubitemid 351398585)
16. Mannerås-Holm L., Leonhardt H., Kullberg J., et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab: 2011; 96 2 E304 E311
17. Littlejohn E. E., Weiss R. E., Deplewski D., Edidin D. V., Rosenfield R. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. J Pediatr Endocrinol Metab: 2007; 20 1 41 51 (Pubitemid 46863537)
18. Rosenfield R. L. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab: 2007; 92 3 787 796 (Pubitemid 46465641)
19. Christensen S. B., Black M. H., Smith N., et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril: 2013; 100 2 470 477
20. Laitinen J., Taponen S., Martikainen H., et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord: 2003; 27 6 710 715 (Pubitemid 36712955)
21. Rich-Edwards J. W., Goldman M. B., Willett W. C., et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol: 1994; 171 1 171 177 (Pubitemid 24254437)
22. Barber T. M., McCarthy M. I., Wass J. A., Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf): 2006; 65 2 137 145 (Pubitemid 44079674)
23. Pasquali R., Gambineri A., Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG: 2006; 113 10 1148 1159 (Pubitemid 44401208)
24. Pinola P., Lashen H., Bloigu A., et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod: 2012; 27 11 3279 3286
25. Strain G. W., Zumoff B., Miller L. K., Rosner W. Sex difference in the effect of obesity on 24-hour mean serum gonadotropin levels. Horm Metab Res: 2003; 35 6 362 366 (Pubitemid 37107440)
26. Taponen S., Martikainen H., Järvelin M. R., et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab: 2003; 88 1 141 147 (Pubitemid 36115156)
27. Randolph J. F. Jr, Sowers M., Gold E. B., et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab: 2003; 88 4 1516 1522 (Pubitemid 36623363)
28. Lim S. S., Norman R. J., Davies M. J., Moran L. J. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev: 2013; 14 2 95 109
29. Moran L. J., Pasquali R., Teede H. J., Hoeger K. M., Norman R. J. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril: 2009; 92 6 1966 1982
30. Escobar-Morreale H. F., Botella-Carretero J. I., Alvarez-Blasco F., Sancho J., San Millán J. L. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab: 2005; 90 12 6364 6369 (Pubitemid 41759284)
31. Eid G. M., Cottam D. R., Velcu L. M., et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis: 2005; 1 2 77 80
32. Jamal M., Gunay Y., Capper A., Eid A., Heitshusen D., Samuel I. Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis. Surg Obes Relat Dis: 2012; 8 4 440 444
33. Legro R. S., Bentley-Lewis R., Driscoll D., Wang S. C., Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab: 2002; 87 5 2128 2133 (Pubitemid 34521498)
34. Reinehr T., de Sousa G., Roth C. L., Andler W. Androgens before and after weight loss in obese children. J Clin Endocrinol Metab: 2005; 90 10 5588 5595 (Pubitemid 41415463)
35. McCartney C. R., Blank S. K., Prendergast K. A., et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab: 2007; 92 2 430 436
36. Wabitsch M., Hauner H., Heinze E., et al. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab: 1995; 80 12 3469 3475
37. Knudsen K. L., Blank S. K., Burt Solorzano C., et al. Hyperandrogenemia in obese peripubertal girls: correlates and potential etiological determinants. Obesity (Silver Spring): 2010; 18 11 2118 2124
38. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev: 1997; 18 6 774 800 (Pubitemid 28009567)
39. Yildiz B. O., Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord: 2007; 8 4 331 342
40. Poretsky L., Cataldo N. A., Rosenwaks Z., Giudice L. C. The insulin-related ovarian regulatory system in health and disease. Endocr Rev: 1999; 20 4 535 582 (Pubitemid 30647079)
41. Arslanian S. A., Lewy V. D., Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab: 2001; 86 1 66 71 (Pubitemid 32109777)
42. Lewy V. D., Danadian K., Witchel S. F., Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr: 2001; 138 1 38 44 (Pubitemid 32097139)
43. Bloch C. A., Clemons P., Sperling M. A. Puberty decreases insulin sensitivity. J Pediatr: 1987; 110 3 481 487 (Pubitemid 17028062)
44. Moran A., Jacobs D. R. Jr, Steinberger J., et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes: 1999; 48 10 2039 2044 (Pubitemid 29458369)
45. Roemmich J. N., Clark P. A., Lusk M., et al. Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release. Int J Obes Relat Metab Disord: 2002; 26 5 701 709 (Pubitemid 34506238)
46. Brufani C., Tozzi A., Fintini D., et al. Sexual dimorphism of body composition and insulin sensitivity across pubertal development in obese Caucasian subjects. Eur J Endocrinol: 2009; 160 5 769 775
47. Pilia S., Casini M. R., Foschini M. L., et al. The effect of puberty on insulin resistance in obese children. J Endocrinol Invest: 2009; 32 5 401 405
48. Vambergue A., Lautier C., Valat A. S., Cortet-Rudelli C., Grigorescu F., Dewailly D. Follow-up study of two sisters with type A syndrome of severe insulin resistance gives a new insight into PCOS pathogenesis in relation to puberty and pregnancy outcome: a case report. Hum Reprod: 2006; 21 5 1274 1278
49. Chakrabarty S., Miller B. T., Collins T. J., Nagamani M. Ovarian dysfunction in peripubertal hyperinsulinemia. J Soc Gynecol Investig: 2006; 13 2 122 129 (Pubitemid 43155845)
50. Ibáñez L., Valls C., Potau N., Marcos M. V., de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab: 2000; 85 10 3526 3530
51. Ibáñez L., Valls C., Ferrer A., Marcos M. V., Rodriguez-Hierro F., de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab: 2001; 86 8 3595 3598 (Pubitemid 32755948)
52. Glueck C. J., Wang P., Fontaine R., Tracy T., Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health: 2001; 29 3 160 169 (Pubitemid 32755792)
53. Arslanian S. A., Lewy V., Danadian K., Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab: 2002; 87 4 1555 1559 (Pubitemid 34615238)
54. De Leo V., Musacchio M. C., Morgante G., Piomboni P., Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod: 2006; 21 9 2252 2256 (Pubitemid 44530597)
55. McCartney C. R. Maturation of sleep-wake gonadotrophin-releasing hormone secretion across puberty in girls: potential mechanisms and relevance to the pathogenesis of polycystic ovary syndrome. J Neuroendocrinol: 2010; 22 7 701 709
56. Apter D., Bützow T., Laughlin G. A., Yen S. S. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab: 1994; 79 1 119 125 (Pubitemid 24221170)
57. McCartney C. R., Prendergast K. A., Blank S. K., Helm K. D., Chhabra S., Marshall J. C. Maturation of luteinizing hormone (gonadotropin-releasing hormone) secretion across puberty: evidence for altered regulation in obese peripubertal girls. J Clin Endocrinol Metab: 2009; 94 1 56 66
58. Chang R. J., Laufer L. R., Meldrum D. R., et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab: 1983; 56 5 897 903 (Pubitemid 13135164)
59. Steingold K., De Ziegler D., Cedars M., et al. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab: 1987; 65 4 773 778 (Pubitemid 17157400)
60. Risma K. A., Clay C. M., Nett T. M., Wagner T., Yun J., Nilson J. H. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci U S A: 1995; 92 5 1322 1326
61. Holte J., Bergh T., Gennarelli G., Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf): 1994; 41 4 473 481 (Pubitemid 24301280)
62. Taylor A. E., McCourt B., Martin K. A., et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab: 1997; 82 7 2248 2256 (Pubitemid 27287593)
63. Arroyo A., Laughlin G. A., Morales A. J., Yen S. S. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab: 1997; 82 11 3728 3733 (Pubitemid 27509362)
64. Pagán Y. L., Srouji S. S., Jimenez Y., Emerson A., Gill S., Hall J. E. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab: 2006; 91 4 1309 1316
65. Srouji S. S., Pagán Y. L., D'Amato F., et al. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endocrinol Metab: 2007; 92 4 1347 1352 (Pubitemid 46556408)
66. Jain A., Polotsky A. J., Rochester D., et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab: 2007; 92 7 2468 2473 (Pubitemid 47037344)
67. Silfen M. E., Denburg M. R., Manibo A. M., et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab: 2003; 88 10 4682 4688 (Pubitemid 37357512)
68. Bordini B., Littlejohn E., Rosenfield R. L. Blunted sleep-related luteinizing hormone rise in healthy premenarcheal pubertal girls with elevated body mass index. J Clin Endocrinol Metab: 2009; 94 4 1168 1175
69. Anderson A. D., Burt Solorzano C., Bhabhra R., et al. The role of hyperinsulinemia vs. insulin resistance in obese girls with hyperandrogenemia. 95th Meeting of the Endocrine Society, San Francisco, CA, June 15-18, 2013; Abstract SUN-505
70. Burt Solorzano C. M., Beller J. P., Abshire M. Y., Collins J. S., McCartney C. R., Marshall J. C. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids: 2012; 77 4 332 337
71. Chhabra S., McCartney C. R., Yoo R. Y., Eagleson C. A., Chang R. J., Marshall J. C. Progesterone inhibition of the hypothalamic gonadotropin- releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab: 2005; 90 5 2810 2815 (Pubitemid 40686328)
72. Blank S. K., McCartney C. R., Chhabra S., et al. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls-implications for regulation of pubertal maturation. J Clin Endocrinol Metab: 2009; 94 7 2360 2366
73. Brothers K. J., Wu S., DiVall S. A., et al. Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor. Cell Metab: 2010; 12 3 295 305
74. Dunaif A., Mandeli J., Fluhr H., Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab: 1988; 66 1 131 139 (Pubitemid 18027742)
75. Morales A. J., Laughlin G. A., Bützow T., Maheshwari H., Baumann G., Yen S. S. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab: 1996; 81 8 2854 2864 (Pubitemid 26326301)
76. Rosenfield R. L., Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res: 2010; 1364 186 197
77. Barbieri R. L., Makris A., Randall R. W., Daniels G., Kistner R. W., Ryan K. J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab: 1986; 62 5 904 910 (Pubitemid 16106715)
78. Gilling-Smith C., Willis D. S., Beard R. W., Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab: 1994; 79 4 1158 1165 (Pubitemid 24342265)
79. Nelson V. L., Legro R. S., Strauss J. F. III, McAllister J. M. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol: 1999; 13 6 946 957 (Pubitemid 30645312)
80. Rosenfield R. L. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am: 1999; 28 2 265 293 (Pubitemid 29242714)
81. Tosi F., Negri C., Perrone F., et al. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2012; 97 5 1712 1719
82. Jakubowicz D. J., Nestler J. E. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab: 1997; 82 2 556 560 (Pubitemid 27068628)
83. Nestler J. E., Jakubowicz D. J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med: 1996; 335 9 617 623 (Pubitemid 26277951)
84. Nestler J. E., Jakubowicz D. J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab: 1997; 82 12 4075 4079 (Pubitemid 27525516)
85. Ehrmann D. A., Schneider D. J., Sobel B. E., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab: 1997; 82 7 2108 2116 (Pubitemid 27287569)
86. Moghetti P., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab: 2000; 85 1 139 146 (Pubitemid 32268804)
87. Komindr S., Kurtz B. R., Stevens M. D., Karas J. G., Bittle J. B., Givens J. R. Relative sensitivity and responsivity of serum cortisol and two adrenal androgens to alpha-adrenocorticotropin-(1-24) in normal and obese, nonhirsute, eumenorrheic women. J Clin Endocrinol Metab: 1986; 63 4 860 864 (Pubitemid 16004287)
88. Moghetti P., Castello R., Negri C., et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab: 1996; 81 3 881 886 (Pubitemid 26083940)
89. Tosi F., Negri C., Brun E., et al. Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur J Endocrinol: 2011; 164 2 197 203
90. Romualdi D., Giuliani M., Draisci G., et al. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril: 2007; 88 1 131 138 (Pubitemid 47001387)
91. Burger H. G. Androgen production in women. Fertil Steril: 2002; 77 04 S3 S5 (Pubitemid 34465837)
92. Quinkler M., Sinha B., Tomlinson J. W., Bujalska I. J., Stewart P. M., Arlt W. Androgen generation in adipose tissue in women with simple obesity-a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol: 2004; 183 2 331 342 (Pubitemid 39562714)
93. Hirshfeld-Cytron J., Barnes R. B., Ehrmann D. A., Caruso A., Mortensen M. M., Rosenfield R. L. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab: 2009; 94 5 1587 1594
94. Rosenfield R. L., Mortensen M., Wroblewski K., Littlejohn E., Ehrmann D. A. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod: 2011; 26 11 3138 3146
95. Stewart P. M., Shackleton C. H., Beastall G. H., Edwards C. R. 5 alpha-reductase activity in polycystic ovary syndrome. Lancet: 1990; 335 8687 431 433 (Pubitemid 20054649)
96. Tsilchorozidou T., Honour J. W., Conway G. S. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab: 2003; 88 12 5907 5913 (Pubitemid 38033071)
97. Fassnacht M., Schlenz N., Schneider S. B., Wudy S. A., Allolio B., Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2003; 88 6 2760 2766 (Pubitemid 36724453)
98. Vassiliadi D. A., Barber T. M., Hughes B. A., et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2009; 94 9 3558 3566
99. Stewart P. M., Boulton A., Kumar S., Clark P. M., Shackleton C. H. Cortisol metabolism in human obesity: impaired cortisone->cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab: 1999; 84 3 1022 1027 (Pubitemid 29138237)
100. Rodin A., Thakkar H., Taylor N., Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med: 1994; 330 7 460 465 (Pubitemid 24058934)
101. DeBoer M. D. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions. Nutrition: 2013; 29 2 379 386
102. Toulis K. A., Goulis D. G., Farmakiotis D., et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update: 2009; 15 3 297 307
103. Gao L., Zhang Y., Cui Y., Jiang Y., Wang X., Liu J. Association of the T45G and G276T polymorphisms in the adiponectin gene with PCOS: a meta-analysis. Gynecol Endocrinol: 2012; 28 2 106 110
104. Lagaly D. V., Aad P. Y., Grado-Ahuir J. A., Hulsey L. B., Spicer L. J. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol: 2008; 284 1-2 38 45
105. Munir I., Yen H. W., Baruth T., et al. Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab: 2005; 90 8 4852 4857 (Pubitemid 41159382)
106. Barber T. M., Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol: 2013; 373 1-2 68 76
107. Roby K. F., Terranova P. F. Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target. Endocrinology: 1990; 126 5 2711 2718 (Pubitemid 20173065)
108. Spaczynski R. Z., Arici A., Duleba A. J. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod: 1999; 61 4 993 998 (Pubitemid 29455636)
109. Mastorakos G., Chrousos G. P., Weber J. S. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab: 1993; 77 6 1690 1694 (Pubitemid 24000936)
110. Päth G., Bornstein S. R., Ehrhart-Bornstein M., Scherbaum W. A. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab: 1997; 82 7 2343 2349 (Pubitemid 27287610)
111. Escobar-Morreale H. F., Luque-Ramírez M., San Millán J. L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev: 2005; 26 2 251 282
112. Escobar-Morreale H. F., Luque-Ramírez M., González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril: 2011; 95 3 1048 1058, e1-e2
113. Repaci A., Gambineri A., Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol: 2011; 335 1 30 41
114. Dumesic D. A., Abbott D. H., Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord: 2007; 8 2 127 141 (Pubitemid 47434646)
115. Abbott D. H., Tarantal A. F., Dumesic D. A. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol: 2009; 71 9 776 784
116. Padmanabhan V., Veiga-Lopez A. Animal models of the polycystic ovary syndrome phenotype. Steroids: 2013; 78 8 734 740
117. Hickey M., Sloboda D. M., Atkinson H. C., et al. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab: 2009; 94 10 3714 3720
118. Anderson H., Fogel N., Grebe S. K., Singh R. J., Taylor R. L., Dunaif A. Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J Clin Endocrinol Metab: 2010; 95 5 2180 2186
119. Barry J. A., Kay A. R., Navaratnarajah R., et al. Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol: 2010; 30 5 444 446
120. Van Wagenen G. Accelerated growth with sexual precocity in female monkeys receiving testosterone propionate. Endocrinology: 1949; 45 5 544 546
121. McGee W. K., Bishop C. V., Bahar A., et al. Elevated androgens during puberty in female rhesus monkeys lead to increased neuronal drive to the reproductive axis: a possible component of polycystic ovary syndrome. Hum Reprod: 2012; 27 2 531 540
122. Diamanti-Kandarakis E., Bourguignon J. P., Giudice L. C., et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev: 2009; 30 4 293 342
123. Eng D. S., Lee J. M., Gebremariam A., Meeker J. D., Peterson K., Padmanabhan V. Bisphenol A and chronic disease risk factors in US children. Pediatrics: 2013; 132 3 e637 e645
124. Zhou W., Liu J., Liao L., Han S., Liu J. Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Mol Cell Endocrinol: 2008; 283 1-2 12 18
125. Takeuchi T., Tsutsumi O., Ikezuki Y., Takai Y., Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J: 2004; 51 2 165 169 (Pubitemid 38657551)
126. Barber T. M., Bennett A. J., Groves C. J., et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia: 2008; 51 7 1153 1158
127. Wehr E., Schweighofer N., Möller R., Giuliani A., Pieber T. R., Obermayer-Pietsch B. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism: 2010; 59 4 575 580
128. Kowalska I., Malecki M. T., Straczkowski M., et al. The FTO gene modifies weight, fat mass and insulin sensitivity in women with polycystic ovary syndrome, where its role may be larger than in other phenotypes. Diabetes Metab: 2009; 35 4 328 331
129. Ewens K. G., Jones M. R., Ankener W., et al. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS ONE: 2011; 6 1 e16390
130. Tan S., Scherag A., Janssen O. E., et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet: 2010; 11 12
131. Wojciechowski P., Lipowska A., Rys P., et al. GIANT Consortium. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia: 2012; 55 10 2636 2645
132. Coviello A. D., Legro R. S., Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab: 2006; 91 2 492 497 (Pubitemid 43236914)
133. Palmert M. R., Gordon C. M., Kartashov A. I., Legro R. S., Emans S. J., Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab: 2002; 87 3 1017 1023 (Pubitemid 36121058)
134. Flannery C. A., Rackow B., Cong X., Duran E., Selen D. J., Burgert T. S. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. Pediatr Diabetes: 2013; 14 1 42 49
135. Wild R. A., Rizzo M., Clifton S., Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril: 2011; 95 3 1073 1079, e1-e11
136. Tasali E., Van Cauter E., Ehrmann D. A. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin: 2008; 3 1 37 46
137. de Sousa G., Schlüter B., Buschatz D., et al. A comparison of polysomnographic variables between obese adolescents with polycystic ovarian syndrome and healthy, normal-weight and obese adolescents. Sleep Breath: 2010; 14 1 33 38
138. Nandalike K., Agarwal C., Strauss T., et al. Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. Sleep Med: 2012; 13 10 1307 1312
139. Dokras A. Mood and anxiety disorders in women with PCOS. Steroids: 2012; 77 4 338 341
140. Trent M. E., Rich M., Austin S. B., Gordon C. M. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med: 2002; 156 6 556 560 (Pubitemid 34596184)
141. McElroy S. L., Kotwal R., Malhotra S., Nelson E. B., Keck P. E., Nemeroff C. B. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry: 2004; 65 5 634 651, quiz 730
142. Trent M., Austin S. B., Rich M., Gordon C. M. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr: 2005; 5 2 107 111 (Pubitemid 40467873)
143. Hollinrake E., Abreu A., Maifeld M., Van Voorhis B. J., Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril: 2007; 87 6 1369 1376 (Pubitemid 46829130)
144. Dieudonne M. N., Pecquery R., Boumediene A., Leneveu M. C., Giudicelli Y. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. Am J Physiol: 1998; 274 6 Pt 1 C1645 C1652
145. Janssen I., Powell L. H., Kazlauskaite R., Dugan S. A. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring): 2010; 18 3 604 610
146. Lovejoy J. C., Bray G. A., Bourgeois M. O., et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women-a clinical research center study. J Clin Endocrinol Metab: 1996; 81 6 2198 2203 (Pubitemid 26175947)
147. Elbers J. M., Asscheman H., Seidell J. C., Megens J. A., Gooren L. J. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab: 1997; 82 7 2044 2047 (Pubitemid 27287559)
148. Gambineri A., Pelusi C., Genghini S., et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf): 2004; 60 2 241 249 (Pubitemid 38200907)
149. Gambineri A., Patton L., Vaccina A., et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab: 2006; 91 10 3970 3980 (Pubitemid 44536872)
150. Corbould A. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diabetes Metab Res Rev: 2008; 24 7 520 532
151. Korhonen S., Hippeläinen M., Vanhala M., Heinonen S., Niskanen L. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril: 2003; 79 6 1327 1334 (Pubitemid 36692831)
152. Apridonidze T., Essah P. A., Iuorno M. J., Nestler J. E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2005; 90 4 1929 1935 (Pubitemid 40586223)
153. Fruzzetti F., Perini D., Lazzarini V., Parrini D., Genazzani A. R. Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol: 2009; 25 5 335 343
154. Holmäng A., Svedberg J., Jennische E., Björntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol: 1990; 259 4 Pt 1 E555 E560 (Pubitemid 20340374)
155. Holmäng A., Larsson B. M., Brzezinska Z., Björntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol: 1992; 262 6 Pt 1 E851 E855
156. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol: 2007; 192 3 585 594 (Pubitemid 46455961)
157. Polderman K. H., Gooren L. J., Asscheman H., Bakker A., Heine R. J. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab: 1994; 79 1 265 271 (Pubitemid 24221194)
158. Diamond M. P., Grainger D., Diamond M. C., Sherwin R. S., Defronzo R. A. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab: 1998; 83 12 4420 4425 (Pubitemid 29100146)